TuHURA Biosciences (HURA) Competitors $2.60 -0.01 (-0.38%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$2.65 +0.05 (+2.08%) As of 04:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HURA vs. ERAS, KOD, CYRX, ETON, BCYC, CMPS, CMPX, RGNX, ITOS, and CRVSShould you be buying TuHURA Biosciences stock or one of its competitors? The main competitors of TuHURA Biosciences include Erasca (ERAS), Kodiak Sciences (KOD), CryoPort (CYRX), Eton Pharmaceuticals (ETON), Bicycle Therapeutics (BCYC), COMPASS Pathways (CMPS), Compass Therapeutics (CMPX), REGENXBIO (RGNX), iTeos Therapeutics (ITOS), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry. TuHURA Biosciences vs. Its Competitors Erasca Kodiak Sciences CryoPort Eton Pharmaceuticals Bicycle Therapeutics COMPASS Pathways Compass Therapeutics REGENXBIO iTeos Therapeutics Corvus Pharmaceuticals TuHURA Biosciences (NASDAQ:HURA) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation. Do insiders and institutionals have more ownership in HURA or ERAS? 0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by insiders. Comparatively, 14.4% of Erasca shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, HURA or ERAS? TuHURA Biosciences has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500. Comparatively, Erasca has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Does the media refer more to HURA or ERAS? In the previous week, TuHURA Biosciences and TuHURA Biosciences both had 3 articles in the media. TuHURA Biosciences' average media sentiment score of 0.98 beat Erasca's score of 0.40 indicating that TuHURA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Erasca 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate HURA or ERAS? TuHURA Biosciences currently has a consensus target price of $12.67, suggesting a potential upside of 387.18%. Erasca has a consensus target price of $3.71, suggesting a potential upside of 53.48%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe TuHURA Biosciences is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TuHURA Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.00Erasca 2 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.38 Is HURA or ERAS more profitable? Erasca's return on equity of -31.19% beat TuHURA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets TuHURA BiosciencesN/A -248.79% -150.83% Erasca N/A -31.19%-26.34% Which has preferable earnings and valuation, HURA or ERAS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTuHURA BiosciencesN/AN/A-$21.68MN/AN/AErascaN/AN/A-$161.65M-$0.45-5.38 SummaryErasca beats TuHURA Biosciences on 6 of the 11 factors compared between the two stocks. Get TuHURA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HURA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HURA vs. The Competition Export to ExcelMetricTuHURA BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$132.86M$3.35B$6.11B$10.54BDividend YieldN/A2.28%5.66%4.69%P/E RatioN/A22.2886.8026.71Price / SalesN/A265.33532.23203.04Price / CashN/A46.3226.3031.09Price / Book7.659.9012.706.57Net Income-$21.68M-$52.45M$3.30B$276.78M7 Day Performance5.26%5.05%3.51%1.96%1 Month Performance1.96%10.61%6.74%9.11%1 Year PerformanceN/A25.03%72.75%31.60% TuHURA Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HURATuHURA Biosciences1.7868 of 5 stars$2.60-0.4%$12.67+387.2%N/A$132.86MN/A0.00N/ANews CoveragePositive NewsERASErasca2.5101 of 5 stars$1.78-3.3%$3.71+108.7%-4.7%$521.95MN/A-3.96120KODKodiak Sciences3.0098 of 5 stars$15.01+57.5%$10.50-30.0%+466.2%$503.39MN/A-3.9590High Trading VolumeCYRXCryoPort3.951 of 5 stars$10.13+1.6%$12.56+23.9%+22.7%$499.17M$228.38M7.621,186Positive NewsETONEton Pharmaceuticals2.232 of 5 stars$18.37+0.2%$29.67+61.5%+184.7%$491.83M$39.01M-114.8120BCYCBicycle Therapeutics3.4825 of 5 stars$7.13+2.9%$22.22+211.7%-64.5%$480.29M$35.28M-2.03240Gap UpCMPSCOMPASS Pathways3.2928 of 5 stars$5.04+2.9%$16.29+223.1%+3.5%$470.11MN/A-2.74120CMPXCompass Therapeutics1.952 of 5 stars$3.49+2.9%$13.88+297.6%+91.7%$468.78M$850K-7.7620Positive NewsRGNXREGENXBIO4.5251 of 5 stars$9.06+1.9%$28.38+213.2%+7.3%$449.07M$83.33M-2.63370ITOSiTeos TherapeuticsN/A$10.15flat$15.50+52.7%N/A$448.73M$35M-2.1790CRVSCorvus Pharmaceuticals1.46 of 5 stars$6.04+2.9%$13.00+115.2%+27.5%$437.40MN/A-5.9830Positive News Related Companies and Tools Related Companies ERAS Competitors KOD Competitors CYRX Competitors ETON Competitors BCYC Competitors CMPS Competitors CMPX Competitors RGNX Competitors ITOS Competitors CRVS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HURA) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TuHURA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TuHURA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
